<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2301244790
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Valencin
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAPTOMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        346.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DR. REDDY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DR. REDDY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Valencin<strong> </strong>powder for solution for injection or infusion is daptomycin. Daptomycin is an antibacterial that can stop the growth of certain bacteria. Valencin is used in adults and in children and adolescents (age from 1 to 17 years) to treat infections of the skin and the tissues below the skin. It is also used to treat infections in the blood when associated with skin infection.</p><p>Valencin is also used in adults to treat infections in the tissues that line the inside of the heart (including heart valves) which are caused by a type of bacteria called <em>Staphyloccocus aureus.</em> It is also used to treat infections in the blood caused by the same type of bacteria when associated with heart infection.</p><p>Depending on the type of infection(s) that you have, your doctor may also prescribe other antibacterials while you are receiving treatment with Valencin.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Valencin: </strong></p><p>-&nbsp; If you are allergic to Daptomycin or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp; If this applies to you, tell your doctor or nurse. If you think you may be allergic, ask your doctor or nurse for advice.<strong> </strong></p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or nurse before you are given Valencin:</p><p>-&nbsp; If you have, or have previously had kidney problems. Your doctor may need to change the dose of Valencin (see section 3 of this leaflet).</p><p>Occasionally, patients receiving Valencin may develop tender or aching muscles or muscle weakness. If this happens tell your doctor (see section 4 of this leaflet for more information). Your doctor will make sure you have a blood test and will advise whether or not to continue with Valencin. The symptoms generally go away within a few days of stopping Valencin.</p><p>-&nbsp; If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores, or serious kidney problems after taking daptomycin.</p><p>-&nbsp; If you are very overweight. There is a possibility that your blood levels of Valencin could be higher than those found in persons of average weight and you may need careful monitoring in case of side effects.</p><p>If any of these applies to you, tell your doctor or nurse before you are given Valencin.</p><p>&nbsp;</p><p><strong>Tell your doctor or health care provider straight away if you develop any of the following symptoms:</strong></p><p>-&nbsp; Serious, acute allergic reactions have been observed in patients treated with nearly all antibacterial agents, including Daptomycin. The symptoms can include wheezing, difficulty breathing, swelling of the face, neck and throat, rashes and hives, or fever.</p><p>-&nbsp; Serious skin disorders have been reported with the use of Daptomycin. The symptoms that occur with these skin disorders can include:</p><p>o&nbsp;&nbsp; a new or worsening fever,</p><p>o&nbsp;&nbsp; red raised or fluid-filled skin spots which may start in your armpits or on your chest or groin areas and which can spread over a large area of your body, -</p><p>o&nbsp;&nbsp; blisters or sores in your mouth or on your genitals</p><p>-&nbsp; A serious kidney problem has been reported with the use of Daptomycin. The symptoms can include fever and rash.</p><p>-&nbsp; Any unusual tingling or numbness of the hands or feet, loss of feeling or difficulties with movements. If this happens, tell your doctor who will decide whether you should continue the treatment.</p><p>-&nbsp; Diarrhoea, especially if you notice blood or mucus, or if diarrhoea becomes severe or persistent.</p><p>-&nbsp; New or worsening fever, cough or difficulty breathing. These may be signs of a rare but serious lung disorder called eosinophilic pneumonia. Your doctor will check the condition of your lungs and decide whether or not you should continue Valencin treatment.</p><p>Valencin may interfere with laboratory tests that measure how well your blood is clotting. The results can suggest poor blood clotting when, in fact, there is no problem. Therefore, it is important that your doctor takes into account that you are receiving Valencin. Please inform your doctor that you are on treatment with Valencin.</p><p>Your doctor will perform blood tests to monitor the health of your muscles both before you start treatment and frequently during treatment with Valencin.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Valencin should not be administered to children below one year of age as studies in animals have indicated that this age group may experience severe side effects.</p><p><strong>Use in elderly </strong></p><p>People over the age of 65 can be given the same dose as other adults, provided their kidneys are working well.</p><p><strong>Other medicines and Valencin</strong></p><p>Tell your doctor or health care provider if you are taking or have recently taken or might take any other medicines.</p><p>It is particularly important that you mention the following: -</p><p>-&nbsp; Medicines called statins or fibrates (to lower cholesterol) or ciclosporin (a medicinal product used in transplantation to prevent organ rejection or for other conditions, e.g. rheumatoid arthritis or atopic dermatitis). It is possible that the risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Valencin. Your doctor may decide not to give you Valencin or to stop the other medicine for a while.</p><p>-&nbsp; Pain killing medicines called non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors (e.g. celecoxib). These could interfere with the effects of Valencin in the kidney.</p><p>-&nbsp; Oral anti-coagulants (e.g. warfarin), which are medicines that prevent blood from clotting. It may be necessary for your doctor to monitor your blood clotting times.</p><p><strong>Pregnancy and breastfeeding</strong></p><p>Valencin is not usually given to pregnant women. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>Do not breast-feed if you are receiving Valencin, because it may pass into your breast milk and could affect the baby.<strong> </strong></p><p><strong>Driving and using machines</strong></p><p>Valencin has no known effects on the ability to drive or use machines.<strong> </strong></p><p><strong>Valencin </strong><strong>contains sodium</strong></p><p>&nbsp;This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Valencin will usually be given to you by a doctor or a health provider</p><p><strong>Adults (18 years of age and above) </strong></p><p>The dose will depend on how much you weigh and the type of infection being treated. The usual dose for adults is 4 mg for every kilogram (kg) of body weight once daily for skin infections or 6 mg for every kg of body weight once daily for a heart infection or a blood infection associated with skin or heart infection. In adult patients, this dose is given directly into your blood stream (into a vein), either as an infusion lasting about 30 minutes or as an injection lasting about 2 minutes. The same dose is recommended in people aged over 65 years provided their kidneys are working well. If your kidneys do not work well, you may receive Valencin less often, e.g. once every other day. If you are receiving dialysis, and your next dose of Valencin is due on a dialysis day, you will be usually given Valencin after the dialysis session.</p><p><strong>Children and adolescents (1 to 17 years of age) </strong></p><p>The dose for children and adolescents (1 to 17 years of age) will depend on the age of patient and the type of infection being treated. This dose is given directly into the blood stream (into a vein), as an infusion lasting about 30-60 minutes.</p><p>A course of treatment usually lasts for 1 to 2 weeks for skin infections. For blood or heart infections and skin infections your doctor will decide how long you should be treated.</p><p>Detailed instructions for use and handling are given at the end of the leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most serious side effects are described below:</p><p><strong>Serious side effects with frequency not known </strong>(frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A hypersensitivity reaction (serious allergic reaction including anaphylaxis and angioedema) has been reported, in some cases during administration of Daptomycin. This serious allergic reaction needs immediate medical attention. Tell your doctor or nurse straight away if you experience any of the following symptoms:</p><p>o&nbsp;&nbsp;&nbsp; Chest pain or tightness,</p><p>o&nbsp;&nbsp;&nbsp; Rash or hives,</p><p>o&nbsp;&nbsp;&nbsp; Swelling around throat,</p><p>o&nbsp;&nbsp;&nbsp; Rapid or weak pulse,</p><p>o&nbsp;&nbsp;&nbsp; Wheezing,</p><p>o&nbsp;&nbsp;&nbsp; Fever,</p><p>o&nbsp;&nbsp;&nbsp; Shivering or trembling,</p><p>o&nbsp;&nbsp;&nbsp; Hot flushes,</p><p>o&nbsp;&nbsp;&nbsp; Dizziness,</p><p>o&nbsp;&nbsp;&nbsp; Fainting,</p><p>o&nbsp;&nbsp;&nbsp; Metallic taste.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor straight away if you experience unexplained muscle pain, tenderness, or weakness. Muscle problems can be serious, including muscle breakdown (rhabdomyolysis), which can result in kidney damage.</p><p>Other serious side effects that have been reported with the use of Daptomycin are: -</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rare but potentially serious lung disorder called eosinophilic pneumonia, mostly after more than 2 weeks of treatment. The symptoms can include difficulty breathing, new or worsening cough, or new or worsening fever. &ndash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin disorders. The symptoms can include:</p><p>o&nbsp;&nbsp;&nbsp; a new or worsening fever,</p><p>o&nbsp;&nbsp;&nbsp; red raised or fluid-filled skin spots which may start in your armpits or on your chest or groin areas and which can spread over a large area of your body,</p><p>o&nbsp;&nbsp;&nbsp; blisters or sores in your mouth or on your genitals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A serious kidney problem. The symptoms can include fever and rash.</p><p>&nbsp;If you experience these symptoms, tell your doctor or nurse straight away. Your doctor will perform additional tests to make a diagnosis.</p><p><strong>Common side effects</strong>&nbsp;(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections such as thrush,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased number of red blood cells (anaemia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, anxiety, difficulty in sleeping,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, weakness (asthenia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High or low blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, abdominal pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, feeling sick (nausea) or being sick (vomiting),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal swelling or bloating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash or itching,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain, itchiness or redness at the site of infusion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in arms or legs,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood testing showing higher levels of liver enzymes or creatine phosphokinase (CPK)</p><p>Other side effects which may occur following Daptomycin treatment are described below:</p><p><strong>Uncommon side effects</strong>&nbsp;(may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood disorders (e.g. increased number of small blood particles called platelets, which may increase the tendency for blood clotting, or higher levels of certain types of white blood cells),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or numbness of the hands or feet, taste disturbance,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trembling,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in heart rhythm, flushes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion (dyspepsia), inflammation of the tongue,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy rash of skin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain, cramping, or weakness, inflammation of the muscles (myositis), joint pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and irritation of the vagina,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; General pain or weakness, tiredness (fatigue),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood test showing increased levels of blood sugar, serum creatinine, myoglobin, or lactate dehydrogenase (LDH), prolonged blood clotting time or imbalance of salts,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy eyes.</p><p><strong>Rare side effects</strong>&nbsp;(may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and eyes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prothrombin time prolonged</p><p><strong>Frequency not known</strong> (frequency cannot be estimated from the available data):</p><p>Antibacterial-associated colitis, including pseudomembranous colitis (severe or persistent diarrhoea containing blood and/or mucus, associated with abdominal pain or fever), easy bruising, bleeding gums, or nosebleeds.<strong> </strong></p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is <strong>Daptomycin</strong>. One vial of powder contains 500 mg daptomycin.</p><p>The other ingredients is sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Daptomycin powder for solution for injection or infusion is supplied as a pale yellow to light brown cake or powder in a glass vial. It is mixed with a solvent to form a liquid before it is administered.
Each carton contains one vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER: </strong></p><p>&nbsp;Sudair Pharma Company (SPC)</p><p>King Fahad Road &ndash;Riyadh Gallery Mall, Gate A1, 3<sup>rd</sup> floor Sudair pharma office, Building &nbsp;7639, Riyadh 12262, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Dr. Reddy&rsquo;s Laboratories Limited FTO-9,</p><p>Plot No. Q1 to Q5, Phase - III, SEZ,</p><p>Duvvada, Visakhapatnam,</p><p>Andhra Pradesh - 530 046, India.</p><p>&nbsp;</p><p>Dr. Reddy&rsquo;s Laboratories Limited, Formulations Unit-11,</p><p>Survey No: 1, 28, 30 to 39,</p><p>APIIC Industrial Park, Pydibhimavaram (V)</p><p>Ranasthalam (M), Srikakulam District - 532409,</p><p>&nbsp;Andhra Pradesh, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في مسحوق فالنسين لتحضير محلول للحقن أو التنقيط الوريدى هي دابتومايسين. دابتومايسين هو مضاد بكتيري يمكن أن يوقف نمو بكتيريا معينة. يُستخدم فالنسين في البالغين وفي الأطفال واليافعين (من عمر سنة إلى 17 سنة) لعلاج عدوى الجلد والأنسجة تحت الجلد. يُستخدم ذلك أيضًا لعلاج عدوى الدم عندما تكون مرتبطة بعدوى الجلد.</p><p dir="RTL">يُستخدم فالنسين كذلك في البالغين لعلاج عدوى الأنسجة المبطّنة للقلب (بما في ذلك صمامات القلب) التي يسببها نوع من البكتيريا يُسمى <em>المكورات العنقودية الذهبية.</em> ويُستخدم أيضًا لعلاج عدوى الدم الناجمة عن نفس نوع البكتيريا عندما يكون ذلك مرتبطًا بعدوى القلب.</p><p dir="RTL">وحسب نوع العدوى لديك، فقد يصف الطبيب كذلك مضادات بكتيرية أخرى بينما تتلقى العلاج باستخدام دابتومايسين.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا ينبغي أن تتلقى فالنسين:</strong><strong> </strong></p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إن كنت مصابًا بالحساسية تجاه دابتومايسين أو أي من المكونات الأخرى بهذا الدواء (مذكورة ضمن القسم 6).</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إن كان ذلك ينطبق عليك، فأبلغ الطبيب أو الممرضة. إن كنت تشك أنك قد تكون مصابًا بالحساسية، فاستشر الطبيب أو الممرضة.<strong> </strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">تحدث إلى الطبيب أو الممرضة قبل أن تتلقى فالنسين:</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إن كنت مصابًا بمشكلات كلوية، أو سبقت إصابتك بها حيث قد يحتاج الطبيب تغيير جرعة فالنسين (انظر القسم 3 من هذه النشرة).</p><p dir="RTL">قد يصاب المرضى الذين يتلقون فالنسين، أحيانًا، بضعف أو ألم بالعضلات. إن حدث ذلك فأبلغ طبيبك (انظر القسم 4 من هذه النشرة لمزيد من المعلومات). سيتأكد الطبيب من أن تخضع لاختبار بالدم وسينصح إما باستمرار استخدام فالنسين أو لا. تزول الأعراض بصفة عامة خلال بضعة أيام من إيقاف فالنسين.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إن سبقت اصابتك بطفح جلدي أو بتقشر الجلد، بثور و/أو قروح بالفم، أو مشكلات كلوية خطيرة بعد تلقي دابتومايسين.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إن كان وزنك زائدًا للغاية. فربما تكون مستويات فالنسين في دمك أعلى مما هي عليه لدى الأشخاص متوسطي الوزن، وقد تحتاج للمراقبة الدقيقة في حالة حدوث آثار الجانبية.</p><p dir="RTL">إن كان أي من ذلك ينطبق عليك، فأبلغ الطبيب أو الممرضة قبل أن تتلقى فالنسين.</p><p>&nbsp;</p><p dir="RTL"><strong>أبلغ الطبيب أو مقدم الرعاية الصحية فورًا إن أصبت بأي من الأعراض التالية:</strong></p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;سبقت ملاحظة تفاعلات حساسية حادة وخطيرة في المرضى الذين تلقوا العلاج بكل العقاقير المضادة للبكتيريا تقريبًا، بما في ذلك دابتومايسين. ويمكن للأعراض أن تتضمن الصفير التنفسي، أو صعوبة التنفس، أو تورم الوجه والعنق والحلق، أو الطفح الجلدي والشري، أو الحمى.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;وردت تقارير بشأن اضطرابات جلد خطيرة مع استخدام دابتومايسين. يمكن للأعراض التي تحدث مع تلك الاضطرابات الجلدية أن تتضمن:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى الجديدة أو المتفاقمة،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع جلدية حمراء مرتفعة أو ممتلئة بالسائل، وهو ما قد يبدأ في إبطيك أو في منطقة الصدر أو المنطقة الأربية (الفخذية)، ويمكن أن ينتشر ذلك إلى منطقة كبيرة من جسمك،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البثور أو القروح في فمك أو على أعضائك التناسلية</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;وردت تقارير بشأن مشكلة كلوية خطيرة مع استخدام دابتومايسين. يمكن للأعراض أن تتضمن الحمى والطفح الجلدي.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;أي تنميل أو خدر غير معتاد في اليدين أو القدمين، أو فقدان الإحساس، أو صعوبات الحركة. إن حدث ذلك، فأبلغ الطبيب الذي سيقرر إن كان ينبغي استمرار العلاج.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;الإسهال، خاصةً إن لاحظت دمًا أو مخاطًا، أو إن صار الإسهال شديدًا أو مستمرًا.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;الحمى الجديدة أو المتفاقمة، أو السعال أو صعوبة التنفس. قد تكون تلك علامات على اضطراب رئوي نادر، لكنه خطير، يُسمى الالتهاب الرئوي اليوزيني. سيتحقق الطبيب من حالة رئتيك وسيقرر إن كان ينبغي أن تستمر في العلاج بفالنسين أم لا.</p><p dir="RTL">يمكن أن يتداخل فالنسين مع اختبارات معملية تقيس مدى كفاءة تجلط دمك. ويمكن للنتائج أن تشير إلى سوء تجلط الدم، بينما لا توجد مشكلة في واقع الأمر. ولذلك، فمن المهم أن يراعي طبيبك أنك تتلقى فالنسين. يُرجى إبلاغ الطبيب إنك قيد العلاج باستخدام فالنسين.</p><p dir="RTL">سيجري الطبيب اختبارات للدم لمراقبة صحة عضلاتك، قبل أن تبدأ العلاج ومن آن إلى آخر أثناء العلاج باستخدام فالنسين.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال واليافعون</strong></p><p dir="RTL">ينبغي عدم إعطاء فالنسين للأطفال الذين تقل أعمارهم عن عام واحد حيث أشارت الدراسات في الحيوانات إلى أن تلك الفئة العمرية يمكن أن تُصاب بآثار جانبية شديدة.</p><p dir="RTL"><strong>الاستخدام في المسنين</strong><strong> </strong></p><p dir="RTL">يمكن أن يتلقى الأشخاص فوق سن 65 عامًا نفس جرعة البالغين الآخرين، بشرط أن تكون الكليتان تؤديان عملهما جيدًا.</p><p dir="RTL"><strong>الأدوية الأخرى وفالنسين</strong></p><p dir="RTL">أبلغ الطبيب أو مقدم الرعاية الصحية إن كنت تتلقى حاليًا، أو إن كنت قد تلقيت مؤخرًا، أو ربما تتلقى أي أدوية أخرى.</p><p dir="RTL">ومن المهم بصفة خاصة أن تذكر ما يلي: -</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;الأدوية التي تسمى أدوية الستاتين أو الفيبرات (تستخدم لخفض مستوى الكوليسترول) أو سيكلوسبورين (منتج دوائي يستخدم في زراعة الأعضاء للوقاية من رفض العضو أو لحالات أخرى، مثل التهاب المفاصل الروماتويدي أو التهاب الجلد التأتبى) حيث من الممكن أن يكون خطر الإصابة بالآثار الجانبية التي تصيب العضلات أعلى عندما يجري تلقي أي من هذه الأدوية (وبعض الأدوية الأخرى التي يمكن أن تؤثر على العضلات) أثناء العلاج باستخدام فالنسين. قد يقرر الطبيب ألا يعطيك فالنسين أو أن يوقف الدواء الآخر لفترة.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;الأدوية المسكنة للألم التي تُسمى الأدوية غير الستيرويدية المضادة للالتهاب (NSAIDs) أو مثبطات إنزيم سيكلوكسيجيناز-2 (COX-2) (مثل سيليكوكسيب) حيث يمكن لذلك أن يتداخل مع تأثيرات فالنسين في الكُلي.</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;مضادات التجلط الفموية (مثل وارفارين)، وهي أدوية تقي من تجلط الدم حيث قد يكون من الضروري لطبيبك أن يراقب مدد تجلط الدم لديك.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يُعطى فالنسين عادةً للنساء الحوامل. إن كنتِ حاملًا أو مُرضعة، أو إن كنتَ تفكرين في الحمل أو تخططين للإنجاب، فاستشيري الطبيب أو الصيدلي قبل أن تتلقي هذا الدواء.</p><p dir="RTL">لا تقومي بالرضاعة الطبيعية إن كنتِ تتلقين فالنسين، لأنه قد يمر في حليب الثدي وقد يؤثر على الرضيع.<strong> </strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس لفالنسين آثار معروفة على القدرة على القيادة أو استخدام الآلات.<strong> </strong></p><p dir="RTL"><strong>يحتوي فالنسين على الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 ملليمول من الصوديوم (23 ملغم) في الجرعة الواحدة، أي أنه يكاد يكون &quot;خاليًا من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُعطى لك فالنسين عادةً بواسطة الطبيب أو مقدم الرعاية الصحية.</p><p dir="RTL"><strong>البالغون (من عمر 18 عامًا فأكبر)</strong><strong> </strong></p><p dir="RTL">ستتوقف الجرعة على مقدار وزنك ونوع العدوى قيد العلاج. الجرعة المعتادة للبالغين هي 4 ملغم لكل كيلوغرام (كغم) من وزن الجسم مرة يوميًا لعدوى الجلد أو 6 ملغم لكل كغم من وزن الجسم مرة يوميًا لعدوى القلب أو لعدوى الدم المرتبطة بعدوى الجلد أو القلب. وفي المرضى البالغين، تُعطى تلك الجرعة في مجرى الدم (في أحد الأوردة) مباشرةً، إما في شكل تنقيط يستمر لحوالي 30 دقيقة، أو كحقنة على مدار حوالي دقيقتين. يوصى بنفس الجرعة لمن تبلغ أعمارهم أكثر من 65 عامًا بشرط أن تكون الكليتان تعملان جيدًا. إن كانت كليتاك لا تعملان جيدًا، فقد تتلقى فالنسين بمعدل أقل تواترًا، وليكن ذلك مثلًا كل يومين. إن كنت تتلقى الغسيل الكلوي، وكان مقررًا أن تكون جرعتك التالية من فالنسين في يوم الغسيل الكلوي، فستتلقى عادةً فالنسين بعد جلسة الغسيل الكلوي.</p><p dir="RTL"><strong>الأطفال واليافعون (من عمر سنة واحدة إلى 17 سنة)</strong><strong> </strong></p><p dir="RTL">ستتوقف جرعة الأطفال واليافعين (من عمر سنة واحدة إلى 17 سنة) على عمر المريض ونوع العدوى قيد العلاج. تُعطى الجرعة في مجرى الدم (في أحد الأوردة) مباشرةً، في شكل تنقيط يستغرق حوالي 30-60 دقيقة.</p><p dir="RTL">تستمر مدة العلاج عادةً لأسبوع أو أسبوعين في حالة عدوى الجلد. وفي حالة عدوى الدم أو القلب وعدوى الجلد، سيقرر الطبيب المدة التي ينبغي أن يستغرقها علاجك.</p><p dir="RTL">تتوفر تعليمات تفصيلية بشأن الاستخدام والتحضير في نهاية النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL">ويرد وصف للآثار الجانبية الأكثر خطورة أدناه:</p><p dir="RTL"><strong>آثار جانبية خطيرة ومعدل شيوعها غير معروف </strong>(لا يمكن تقدير معدل التواتر من واقع البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وردت تقارير بشأن تفاعل فرط الحساسية (تفاعل حساسية خطير بما في ذلك التأق والوذمة الوعائية)، في بعض الحالات أثناء إعطاء دابتومايسين. ويتطلب تفاعل الحساسية الخطير هذا العناية الطبية الفورية. أبلغ الطبيب أو الممرضة فورًا إن أصبت بأي من الأعراض التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضيق في الصدر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو شرى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم حول الحلق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبض سريع أو ضعيف</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز أو صفير عند التنفس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف أو ارتعاش</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبّات الساخنة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مذاق أو شعور بطعم معدن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغ الطبيب فورًا إن أصبت بألم أو ألم عند اللمس أو بضعف غير مبرر بالعضلات. قد تكون مشكلات العضلات خطيرة، بما في ذلك انحلال العضلات (انحلال الربيدات)، الذي يمكن أن يؤدي إلى تلف الكلية.</p><p dir="RTL">تتضمن الآثار الجانبية الخطيرة الأخرى التي وردت تقارير بشأنها في حالة استخدام دابتومايسين ما يلي: -</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب رئوي نادر، وإن كان يحتمل أن يكون خطيرًا، يُسمى الالتهاب الرئوي اليوزيني، ويكون ذلك غالبًا بعد مرور أكثر من أسبوعين من العلاج. يمكن أن تشمل الأعراض صعوبة التنفس، أو سعال جديد أو متفاقم، أو حمى جديدة أو متفاقمة. &ndash;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات الجلدية الخطيرة. يمكن للأعراض أن تشمل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى جديدة أو متفاقمة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع حمراء نافرة أو ممتلئة بسائل في الجلد، وهو ما قد يبدأ في إبطيك أو في منطقة الصدر أو في المنطقة الأُربية، ويمكن أن ينتشر ذلك إلى منطقة كبيرة من جسمك.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور أو قروح في فمك أو على أعضائك التناسلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة كلوية خطيرة. يمكن للأعراض أن تتضمن الحمى والطفح الجلدي.</p><p dir="RTL">&nbsp;إن أصابتك تلك الأعراض، فأبلغ الطبيب أو الممرضة فورًا. سيجري الطبيب اختبارات إضافية للتوصل إلى تشخيص.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تصيب ما يصل إلى شخص من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية، مثل السلاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد خلايا الدم الحمراء (فقر الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة، قلق، وصعوبة في النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، ضعف (الوهن)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو انخفاضه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك، ألم البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، شعور بالغثيان أو الإصابة بالقيء،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امتلاء البطن بالغازات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم البطن أو انتفاخه بالغازات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، حكة، أو احمرار في موضع التنقيط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين أو الساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبين اختبارات الدم مستويات أعلى من إنزيمات الكبد أو الكرياتين فوسفوكيناز (CPK)</p><p dir="RTL">قد تحدث آثار جانبية أخرى بعد العلاج باستخدام دابتومايسين وهي موصوفة أدناه:</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة</strong> (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم (مثل زيادة عدد جسيمات صغيرة في الدم تسمى الصفائح الدموية، وهو ما قد يزيد من القابلية لتجلط الدم، أو ارتفاع مستويات أنواع معينة من خلايا الدم البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنميل أو الخدر في اليدين أو القدمين، اضطراب المذاق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في إيقاع نبض القلب، احمرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الهضم (عسر الهضم)، التهاب اللسان،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مصاحب للحكة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات، تقلصات، أو ضعف، التهاب العضلات (الالتهاب العضلي)، ألم المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المهبل وتهيجه،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف عام، تعب (إرهاق).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُبين اختبار الدم ارتفاع مستويات سكر الدم، الكرياتينين، ميوغلوبين ، أو إنزيم نازع لهيدروجين اللاكتات &nbsp;لاكتات ديهيدروجينيز (LDH) &nbsp;، زيادة مدة تجلط الدم، أو اضطراب الأملاح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في العينين.</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong> (قد تصيب ما يصل إلى شخص واحد من كل 1,000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعينين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة زمن البروثرومبين (بروتين ينتجه الكبد يساعد في تخثر الدم بشكل ملائم)</p><p dir="RTL"><strong>آثار جانبية معدل شيوعها غير معروف </strong>(لا يمكن تقدير معدل التواتر من واقع البيانات المتاحة):</p><p dir="RTL">التهاب القولون المرتبط بالمضادات الحيوية، بما في ذلك التهاب القولون الغشائي الكاذب (إسهال شديد أو مستمر الذي يحتوي على دم و/أو مخاط، والذي يصاحبه ألم البطن أو حمى)، سهولة الإصابة بالكدمات، نزيف اللثة، أو نزيف الأنف.<strong> </strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;الطبيب&gt; &lt;أو&gt; &lt;مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُخزن في الثلاجة (في درجة حرارة 2-8 مئوية).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي <strong>دابتومايسين</strong>. تحتوي قارورة المسحوق الواحدة على 500 ملغم من دابتومايسين.<br />والمحتويات الأخرى هي هيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر مسحوق دابتومايسين للحقن أو للتنقيط الوريدي في شكل مسحوق أو قالب أصفر باهت أو بني فاتح في قارورة زجاجية. وهو يُخلط بمُذيب لتكوين سائل قبل إعطائه.</p><p dir="RTL">تحتوي كل عبوة كرتونية على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق:</strong><strong> </strong></p><p dir="RTL">&nbsp;شركة سدير للأدوية (SPC)</p><p dir="RTL">طريق الملك فهد - الرياض جاليري مول ، البوابة A1، الطابق الثالث، مكتب شركة سدير للأدوية، المبنى 7639، الرياض 12262، المملكة العربية السعودية</p><p dir="RTL">الهاتف: 920001432-11-966+</p><p dir="RTL">الفاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p>&nbsp;</p><p dir="RTL"><strong>المصنّع:</strong></p><p dir="RTL">د. ريديز لابوراتوريز المحدودة إف تي أو-9،</p><p dir="RTL">القطعة رقم Q1 إلى Q5، المرحلة الثالثة، إس إي زد</p><p dir="RTL">دوفادا، فيزاخاباتنام</p><p dir="RTL">أندرا براديش &ndash; 046 530، الهند</p><p>&nbsp;</p><p dir="RTL">&nbsp;د. ريديز لابوراتوريز المحدودة إف تي أو-9، وحدة التركيبات- 11،</p><p dir="RTL">رقم الاستبيان: 1 و28 و30 إلى 39،</p><p dir="RTL">حديقة APIIC الصناعية، بيديبيمافارام (V)</p><p dir="RTL">راناساثالام (M)، مقاطعة سريكاكولام &ndash; 532409،</p><p dir="RTL">&nbsp;أندرا براديش، الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valencin 500 mg powder for solution for injection/infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5ml of solution contains:
Daptomycin 500 mg
Sodium Hydroxide q.s
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valencin is indicated for the treatment of the following infections.</p><p>- Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).</p><p>- Adult patients with right-sided infective endocarditis (RIE) due to <em>Staphylococcus aureus</em>. It is recommended that the decision to use Valencin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.</p><p>- Adult and paediatric (1 to 17 years of age) patients with&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.</p><p>Valencin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Valencin should be co-administered with appropriate antibacterial agent(s).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical studies in patients employed infusion of Valencin over 30 minutes. There is no clinical experience in patients with the administration of Valencin as an injection over 2 minutes. This mode of administration was only studied in healthy subjects. However, when compared with the same doses given as intravenous infusions over 30 minutes there were no clinically important differences in the pharmacokinetics and safety profile of Valencin (see also sections 4.8 and 5.2).</p><p><u>Posology</u></p><p><u>Adults</u></p><p>- cSSTI without concurrent <em>Staphylococcus aureus</em> bacteraemia: Valencin 4 mg/kg is administered once every 24 hours for 7-14 days or until the infection is resolved (see section 5.1).</p><p>- cSSTI with concurrent <em>Staphylococcus aureus</em> bacteraemia: Valencin 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The duration of therapy may need to be longer than 14 days in accordance with the perceived risk of complications in the individual patient.</p><p>- Known or suspected right-sided infective endocarditis due to <em>Staphylococcus aureus</em>: Valencin 6 mg/kg is administered once every 24 hours. See below for dose adjustments in patients with renal impairment. The duration of therapy should be in accordance with available official recommendations.</p><p>Valencin is administered intravenously in 0.9% sodium chloride (see section 6.6). Valencin should not be used more frequently than once a day.</p><p>Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p><p><em><u>Renal impairment </u></em></p><p>Valencin is eliminated primarily by the kidney.</p><p>Due to limited clinical experience (see table and footnotes below), Valencin should only be used in adult patients with any degree of renal impairment (CrCl &lt; 80 ml/min) when it is considered that the expected clinical benefit outweighs the potential risk. The response to treatment, renal function and creatine phosphokinase (CPK) levels should be closely monitored in all patients with any degree of renal impairment. &nbsp;(see also sections 4.4 and 5.2). The dosage regimen for Valencin in paediatric patients with renal impairment has not been established.</p><p>Dose adjustments in patients with renal impairment by indication and creatinine clearance.</p><table border="1" cellspacing="0" cellpadding="0" style="width:492px"><tbody><tr><td><p><strong>Indication for use </strong></p></td><td><p><strong>Creatinine clearance</strong></p></td><td><p><strong>Dose recommendation </strong></p></td><td style="vertical-align:top"><p><strong>Comments</strong></p></td></tr><tr><td rowspan="2"><p>Complicated skin and soft-tissue infections (cSSTI) without <em>S. aureus</em> bacteraemia (SAB)</p></td><td><p>&ge; 30 ml/min</p></td><td><p>4 mg/kg once daily</p></td><td><p>See section 5.1</p></td></tr><tr><td><p>&lt; 30 ml/min</p></td><td><p>4 mg/kg every 48 hours</p></td><td><p>(1, 2)</p></td></tr><tr><td rowspan="2"><p>RIE or cSSTI associated with <em>S. aureus</em> bacteraemia (SAB)</p></td><td><p>&ge; 30 ml/min</p></td><td><p>6 mg/kg once daily</p></td><td><p>See section 5.1</p></td></tr><tr><td><p>&lt; 30 ml/min</p></td><td><p>6 mg/kg every 48 hours</p></td><td><p>(1, 2)</p><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>cSSTI = complicated skin and soft-tissue infections; SAB =&nbsp;<em>S. aureus&nbsp;</em>bacteraemia</p><p>(1) The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is based on pharmacokinetic studies and modelling results (see sections 4.4 and 5.2).</p><p>(2) The same dose adjustments, which are based on pharmacokinetic data in volunteers including PK modelling results, are recommended for adult patients on haemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Whenever possible, Valencin should be administered following the completion of dialysis on dialysis days (see section 5.2).</p></td></tr></tbody></table><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary when administering Valencin to patients with mild or moderate hepatic impairment (Child-Pugh Class B) (see section 5.2).. No data are available in patients with severe hepatic impairment (Child-Pugh Class C). Therefore caution should be exercised if Valencin is given to such patients.</p><p><em>Elderly patients</em></p><p>The recommended doses should be used in elderly patients except those with severe renal impairment (see above and section 4.4)</p><p><em>Paediatric patients (1 to 17 years of age)</em></p><p>The recommended dosage regimens based on age and indication are shown below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="3"><p><strong>Age Group</strong></p></td><td colspan="4"><p><strong>Indication</strong></p></td></tr><tr><td colspan="2"><p><strong>cSSTI without SAB</strong></p></td><td colspan="2"><p><strong>cSSTI associated with SAB</strong></p></td></tr><tr><td><p><strong>Dosage Regimen</strong></p></td><td><p><strong>Duration of Therapy</strong></p></td><td><p><strong>Dosage Regimen</strong></p></td><td><p><strong>Duration of Therapy</strong></p></td></tr><tr><td><p>12 to 17 years</p></td><td><p>5 mg/kg once every 24 hours infused over 30 minutes</p></td><td rowspan="4"><p>Up to 14 days</p></td><td><p>7 mg/kg once every 24 hours infused over 30 minutes</p></td><td rowspan="4"><p>(1)</p></td></tr><tr><td><p>7 to 11 years</p></td><td><p>7 mg/kg once every 24 hours infused over 30 minutes</p></td><td><p>9 mg/kg once every 24 hours infused over 30 minutes</p></td></tr><tr><td><p>2 to 6 years</p></td><td><p>9 mg/kg once every 24 hours infused over 60 minutes</p></td><td><p>12 mg/kg once every 24 hours infused over 60 minutes</p></td></tr><tr><td><p>1 to &lt; 2 years</p></td><td><p>10 mg/kg once every 24 hours infused over 60 minutes</p></td><td><p>12 mg/kg once every 24 hours infused over 60 minutes</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>cSSTI = complicated skin and soft-tissue infections; SAB =&nbsp;<em>S. aureus&nbsp;</em>bacteraemia;</p><p>(1) Minimum duration of Valencin for paediatric SAB should be in accordance with the perceived risk of complications in the individual patient. The duration of Valencin may need to be longer than 14 days in accordance with the perceived risk of complications in the individual patient. In the paediatric SAB study, the mean duration of IV Valencin was 12 days, with a range of 1 to 44 days. The duration of therapy should be in accordance with available official recommendations.</p></td></tr></tbody></table><p>&nbsp;</p><p>Valencin is administered intravenously in 0.9 % sodium chloride. Valencin should not be used more frequently than once a day</p><p>Creatine phosphokinase (CPK) levels must be measured at baseline and at regular intervals (at least weekly) during treatment (see section 4.4).</p><p>Paediatric patients below the age of one year should not be given Valencin due to the risk of potential effects on muscular, neuromuscular and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><p><u>Method of administration</u></p><p>In adults, Valencin is given by intravenous infusion (see section 6.6). &nbsp;and administered over a 30-minute period or by intravenous injection (see section 6.6). and administered over a 2-minute period.</p><p>In paediatric patients aged 7 to 17 years, Valencin is given by intravenous infusion over a 30-minute period (see section 6.6). In paediatric patients aged 1 to 6 years, Valencin is given by intravenous infusion over a 60-minute period (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>If a focus of infection other than cSSTI or RIE is identified after initiation of Valencin therapy consideration should be given to instituting alternative antibacterial therapy that has been demonstrated to be efficacious in the treatment of the specific type of infection(s) present.</p><p>&nbsp;</p><p><u>Anaphylaxis/hypersensitivity reactions</u></p><p>Anaphylaxis/hypersensitivity reactions have been reported with Valencin. If an allergic reaction to Valencin occurs, discontinue use and institute appropriate therapy.</p><p><u>Pneumonia</u></p><p>It has been demonstrated in clinical studies that Valencin is not effective in the treatment of pneumonia. Valencin is therefore not indicated for the treatment of pneumonia.</p><p><u>RIE due to </u><em><u>Staphylococcus aureus</u></em></p><p>Clinical data on the use of Valencin to treat RIE due to <em>Staphylococcus aureus</em> are limited to 19 patients (see &ldquo;Information from clinical trials&rdquo; in section 5.1). The safety and efficacy of Valencin in children and adolescents aged below 18 years with right-sided infective endocarditis (RIE) due to&nbsp;<em>Staphylococcus aureus</em>&nbsp;have not been established.</p><p>The efficacy of Valencin in patients with prosthetic valve infections or with left-sided infective endocarditis due to <em>Staphylococcus aureus</em> has not been demonstrated.</p><p><u>Deep-seated infections</u></p><p>Patients with deep-seated infections should receive any required surgical interventions (e.g. debridement, removal of prosthetic devices, valve replacement surgery) without delay.</p><p><u>Enterococcal infections</u></p><p>There is insufficient evidence to be able to draw any conclusions regarding the possible clinical efficacy of Valencin against infections due to enterococci, including Enterococcus faecalis and Enterococcus faecium. In addition, dose regimens of Valencin that might be appropriate for the treatment of enterococcal infections, with or without bacteraemia, have not been identified. Failures with Valencin in the treatment of enterococcal infections that were mostly accompanied by bacteraemia have been reported. In some instances treatment failure has been associated with the selection of organisms with reduced susceptibility or frank resistance to Valencin (see section 5.1).</p><p><u>Non-susceptible micro-organisms</u></p><p>The use of antibacterials may promote the overgrowth of non-susceptible micro-organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><em><u>Clostridioides difficile</u></em><u>-associated diarrhoea</u></p><p><em>Clostridioides difficile</em>-associated diarrhoea (CDAD) has been reported with Valencin(see section 4.8). If CDAD is suspected or confirmed, Valencin may need to be discontinued and appropriate treatment instituted as clinically indicated.</p><p><u>Drug/laboratory test interactions</u></p><p>False prolongation of prothrombin time (PT) and elevation of international normalised ratio (INR) have been observed when certain recombinant thromboplastin reagents are utilised for the assay (see also section 4.5).</p><p><u>Creatine phosphokinase and myopathy</u></p><p>Increases in plasma creatine phosphokinase (CPK; MM isoenzyme) levels associated with muscular pains and/or weakness and cases of myositis, myoglobinaemia and rhabdomyolysis have been reported during therapy with Valencin. In clinical studies, marked increases in plasma CPK to &gt; 5x Upper Limit of Normal (ULN) without muscle symptoms occurred more commonly in Valencin-treated patients (1.9%) than in those that received comparators (0.5%). Therefore, it is recommended that:</p><p>&bull; Plasma CPK should be measured at baseline and at regular intervals (at least once weekly) during therapy in all patients.</p><p>&bull; CPK should be measured more frequently (e.g. every 2-3 days at least during the first two weeks of treatment) in patients who are at higher risk of developing myopathy. For example, patients with any degree of renal impairment (creatinine clearance &lt; 80 ml/min), including those on haemodialysis or CAPD, and patients taking other medicinal products known to be associated with myopathy (e.g. HMG-CoA reductase inhibitors, fibrates and ciclosporin).</p><p>&bull; It cannot be ruled out that those patients with CPK greater than 5 times upper limit of normal at baseline may be at increased risk of further increases during Valencin therapy. This should be taken into account when initiating Valencin therapy and, if Valencin is given, these patients should be monitored more frequently than once weekly.</p><p>&bull; Valencin should not be administered to patients who are taking other medicinal products associated with myopathy unless it is considered that the benefit to the patient outweighs the risk.</p><p>&bull; Patients should be reviewed regularly while on therapy for any signs or symptoms that might represent myopathy.</p><p>&bull; Any patient that develops unexplained muscle pain, tenderness, weakness or cramps should have CPK levels monitored every 2 days. Valencin should be discontinued in the presence of unexplained muscle symptoms if the CPK level reaches greater than 5 times upper limit of normal.</p><p><u>Peripheral neuropathy</u></p><p>Patients who develop signs or symptoms that might represent a peripheral neuropathy during therapy with Valencin should be investigated and consideration should be given to discontinuation of Valencin (see sections 4.8 and 5.3).</p><p><u>Paediatric population</u></p><p>Paediatric patients below the age of one year should not be given Valencin due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) that were observed in neonatal dogs (see section 5.3).</p><p><u>Eosinophilic pneumonia</u></p><p>Eosinophilic pneumonia has been reported in patients receiving Valencin. In most reported cases associated with Valencin, patients developed fever, dyspnoea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates or organising pneumonia. The majority of cases occurred after more than 2 weeks of treatment with Valencin and improved when Valencin was discontinued and steroid therapy was initiated. Recurrence of eosinophilic pneumonia upon re-exposure has been reported. Patients who develop these signs and symptoms while receiving Valencin should undergo prompt medical evaluation, including, if appropriate, bronchoalveolar lavage, to exclude other causes (e.g. bacterial infection, fungal infection, parasites and other medicinal products). Valencin should be discontinued immediately and treatment with systemic steroids should be initiated when appropriate.</p><p><u>Severe cutaneous adverse reactions</u></p><p>Severe cutaneous adverse reactions (SCARs) including drug reaction with eosinophilia and systemic symptoms (DRESS) and vesiculobullous rash with or without mucous membrane involvement (Stevens‑Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN)), which could be life-threatening or fatal, have been reported with Valencin. At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored. If signs and symptoms suggestive of these reactions appear, Valencin should be discontinued immediately and an alternative treatment should be considered. If the patient has developed a severe cutaneous adverse reaction with the use of Valencin, treatment with Valencin must not be restarted in this patient at any time.</p><p><u>Tubulointerstitial nephritis</u></p><p>Tubulointerstitial nephritis (TIN) has been reported in post-marketing experience with Valencin. Patients who develop fever, rash, eosinophilia and/or new or worsening renal impairment while receiving Valencin should undergo medical evaluation. If TIN is suspected, Valencin should be discontinued promptly and appropriate therapy and/or measures should be taken.</p><p><u>Renal impairment</u></p><p>Renal impairment has been reported during treatment with Valencin. Severe renal impairment may in itself also pre-dispose to elevations in Valencin levels which may increase the risk of development of myopathy.</p><p>An adjustment of Valencin dose interval is needed for patients whose creatinine clearance is &lt; 30 ml/min (see sections 4.2 and 5.2). The safety and efficacy of the dose interval adjustment have not been evaluated in controlled clinical trials and the recommendation is mainly based on pharmacokinetic modelling data. Valencin should only be used in such patients when it is considered that the expected clinical benefit outweighs the potential risk.</p><p>Caution is advised when administering Valencin to patients who already have some degree of renal impairment (creatinine clearance &lt; 80 ml/min) before commencing therapy with Valencin. Regular monitoring of renal function is advised (see also section 5.2).</p><p>In addition, regular monitoring of renal function is advised during concomitant administration of potentially nephrotoxic agents, regardless of the patient&#39;s pre-existing renal function (see also section 4.5).</p><p>The dosage regimen for Valencin in paediatric patients with renal impairment has not been established.</p><p><u>Obesity</u></p><p>In obese subjects with Body Mass Index (BMI) &gt; 40 kg/m<sup>2</sup> but with creatinine clearance &gt; 70 ml/min, the AUC<sub>0-&infin;</sub> Valencin was significantly increased (mean 42% higher) compared with non-obese matched controls. There is limited information on the safety and efficacy of Valencin in the very obese and so caution is recommended. However, there is currently no evidence that a dose reduction is required (see section 5.2).</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valencin undergoes little to no Cytochrome P450 (CYP450)-mediated metabolism. It is unlikely that Valencin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>Interaction studies for Valencin were performed with aztreonam, tobramycin, warfarin and probenecid. Valencin had no effect on the pharmacokinetics of warfarin or probenecid, nor did these medicinal products alter the pharmacokinetics of Valencin. The pharmacokinetics of Valencin were not significantly altered by aztreonam.</p><p>Although small changes in the pharmacokinetics of Valencin and tobramycin were observed during co-administration by intravenous infusion over a 30-minute period using a Valencin dose of 2 mg/kg, the changes were not statistically significant. The interaction between Valencin and tobramycin with an approved dose of Valencin is unknown. Caution is warranted when Valencin is co-administered with tobramycin.</p><p>Experience with the concomitant administration of Valencin and warfarin is limited. Studies of Valencin with anticoagulants other than warfarin have not been conducted. Anticoagulant activity in patients receiving Valencin and warfarin should be monitored for the first several days after therapy with Valencin is initiated.</p><p>There is limited experience regarding concomitant administration of Valencin with other medicinal products that may trigger myopathy (e.g. HMG-CoA reductase inhibitors). However, some cases of marked rises in CPK levels and cases of rhabdomyolysis occurred in adult patients taking one of these medicinal products at the same time as Valencin. It is recommended that other medicinal products associated with myopathy should if possible be temporarily discontinued during treatment with Valencin unless the benefits of concomitant administration outweigh the risk. If co-administration cannot be avoided, CPK levels should be measured more frequently than once weekly and patients should be closely monitored for any signs or symptoms that might represent myopathy. See sections 4.4, 4.8 and 5.3</p><p>Valencin is primarily cleared by renal filtration and so plasma levels may be increased during co-administration with medicinal products that reduce renal filtration (e.g. NSAIDs and COX-2 inhibitors). In addition, there is a potential for a pharmacodynamic interaction to occur during co-administration due to additive renal effects. Therefore, caution is advised when Valencin is co-administered with any other medicinal product known to reduce renal filtration.</p><p>During post&ndash;marketing surveillance, cases of interference between Valencin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported. This interference led to a false prolongation of PT and elevation of INR. If unexplained abnormalities of PT/INR are observed in patients taking Valencin, consideration should be given to a possible <em>in vitro</em> interaction with the laboratory test. The possibility of erroneous results may be minimized by drawing samples for PT or INR testing near the time of trough plasma concentrations of Valencin (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>No clinical data on pregnancies are available for Valencin. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).</p><p>Valencin should not be used during pregnancy unless clearly necessary i.e., only if the expected benefit outweighs the possible risk.</p><p><u>Breast-feeding</u></p><p>In a single human case study, Valencin was intravenously administered daily for 28 days to a nursing mother at a dose of 500 mg/day, and samples of the patient&#39;s breast milk were collected over a 24-hour period on day 27. The highest measured concentration of Valencin in the breast milk was 0.045 &micro;g/ml, which is a low concentration. Therefore, until more experience is gained, breast-feeding should be discontinued when Valencin is administered to nursing women.</p><p><u>Fertility</u></p><p>No clinical data on fertility are available for Valencin. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>On the basis of reported adverse drug reactions, Valencin is presumed to be unlikely to produce an effect on the ability to drive or use machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In clinical studies, 2,011 adult subjects received Valencin. Within these trials, 1,221 subjects received a daily dose of 4 mg/kg, of whom 1,108 were patients and 113 were healthy volunteers; 460 subjects received a daily dose of 6 mg/kg, of whom 304 were patients and 156 were healthy volunteers. In paediatric studies, 372 patients received Valencin, of whom 61 received a single dose and 311 received a therapeutic regimen for cSSTI or SAB (daily doses ranged from 4 mg/kg to 12 mg/kg). Adverse reactions (i.e. considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported at similar frequencies for Valencin and comparator regimens.</p><p>The most frequently reported adverse reactions (frequency common (&ge; 1/100 to &lt; 1/10)) are:</p><p>Fungal infections, urinary tract infection, candida infection, anaemia, anxiety, insomnia, dizziness, headache, hypertension, hypotension, gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension, liver function tests abnormal (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP)), rash, pruritus, limb pain, serum creatine phosphokinase (CPK) increased, infusion site reactions, pyrexia, asthenia.</p><p>Less frequently reported, but more serious, adverse reactions include hypersensitivity reactions, eosinophilic pneumonia (occasionally presenting as organising pneumonia), drug reaction&nbsp; with eosinophilia and systemic symptoms (DRESS), angioedema and rhabdomyolysis.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions were reported during therapy and during follow-up with frequencies corresponding to very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data):</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Table 1 Adverse reactions from clinical studies and post-marketing reports</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse reactions</strong></p></td></tr><tr><td rowspan="3"><p>Infections and infestations</p></td><td><p><em>Common:</em></p></td><td><p>Fungal infections, urinary tract infection, candida infection</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Fungaemia</p></td></tr><tr><td><p><em>Not known<sup>*</sup>:</em></p></td><td><p>Clostridium difficile-associated diarrhoea<sup>**</sup></p></td></tr><tr><td rowspan="4"><p>Blood and lymphatic system disorders</p></td><td><p><em>Common:</em></p></td><td><p>Anaemia</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Thrombocythaemia, eosinophilia, international normalised ratio (INR) increased, leukocytosis</p></td></tr><tr><td><p><em>Rare:</em></p></td><td><p>Prothrombin time (PT) prolonged</p></td></tr><tr><td><p><em>Not Known<sup>*</sup></em></p></td><td><p>Thrombocytopaenia</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p><em>Not known<sup>*</sup>:</em></p><p>&nbsp;</p></td><td><p>Hypersensitivity<sup>**</sup>, manifested by isolated spontaneous reports including, but not limited to angioedema, pulmonary eosinophilia, sensation of oropharyngeal swelling, anaphylaxis<sup>**</sup>, infusion reactions including the following symptoms: tachycardia, wheezing, pyrexia, rigors, systemic flushing, vertigo, syncope and metallic taste</p><p>&nbsp;</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p><em>Uncommon:</em></p></td><td><p>Decreased appetite, hyperglycaemia, electrolyte imbalance</p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p><em>Common:</em></p></td><td><p>Anxiety, insomnia</p></td></tr><tr><td rowspan="3"><p>Nervous system disorders</p></td><td><p><em>Common:</em></p></td><td><p>Dizziness, headache</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Paraesthesia, taste disorder, tremor, eye irritation</p></td></tr><tr><td><p><em>Not known<sup>*</sup>:</em></p></td><td><p>Peripheral neuropathy<sup>**</sup></p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p><em>Uncommon:</em></p></td><td><p>Vertigo</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p><em>Uncommon:</em></p></td><td><p>Supraventricular tachycardia, extrasystole</p></td></tr><tr><td rowspan="2"><p>Vascular disorders</p></td><td><p><em>Common:</em></p></td><td><p>Hypertension, hypotension</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Flushes</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p><em>Not known<sup>*</sup>:</em></p></td><td><p>Eosinophilic pneumonia<sup>1**</sup>, cough</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p><em>Common:</em></p></td><td><p>Gastrointestinal and abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence, bloating and distension</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Dyspepsia, glossitis</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary disorders</p></td><td><p><em>Common:</em></p></td><td><p>Liver function tests abnormal<sup>2</sup> (increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP))</p></td></tr><tr><td><p><em>Rare:</em></p></td><td><p>Jaundice</p></td></tr><tr><td rowspan="3"><p>Skin and subcutaneous tissue disorders</p></td><td><p><em>Common:</em></p></td><td><p>Rash, pruritus</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Urticaria</p></td></tr><tr><td><p><em>Not known<sup>*</sup></em></p></td><td><p>Acute generalised exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>**</sup>, vesiculobullous rash with or without mucous membrane involvement (SJS or TEN)<sup>**</sup></p></td></tr><tr><td rowspan="3"><p>Musculoskeletal and connective tissue disorders</p></td><td><p><em>Common:</em></p></td><td><p>Limb pain, serum creatine phosphokinase (CPK)<sup>2</sup> increased</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Myositis, increased myoglobin, muscular weakness, muscle pain, arthralgia, serum lactate dehydrogenase (LDH) increased, muscle cramps</p></td></tr><tr><td><p><em>Not known<sup>*</sup>:</em></p></td><td><p>Rhabdomyolysis<sup>3 **</sup></p></td></tr><tr><td rowspan="2"><p>Renal and urinary disorders</p></td><td><p><em>Uncommon:</em></p></td><td><p>Renal impairment, including renal failure and renal insufficiency, serum creatinine increased</p></td></tr><tr><td><p><em>Not known<sup>*</sup>:</em></p></td><td><p><em>Tubulointerstitial nephritis (TIN)<sup>**</sup></em></p></td></tr><tr><td><p>Reproductive system and breast disorders</p></td><td><p><em>Uncommon:</em></p></td><td><p>Vaginitis</p></td></tr><tr><td rowspan="2"><p>General disorders and administration site conditions</p></td><td><p><em>Common:</em></p></td><td><p>Infusion site reactions, pyrexia, asthenia</p></td></tr><tr><td><p><em>Uncommon:</em></p></td><td><p>Fatigue, pain</p></td></tr></tbody></table><p><em><sup>* </sup></em><em>Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.</em></p><p><sup>**</sup><em> </em><em>See section 4.4.</em></p><p><em><sup>1</sup></em><em> While the exact incidence of eosinophilic pneumonia associated with Valencin is unknown, to date the reporting rate of spontaneous reports is very low (&lt; 1/10,000).</em></p><p><em><sup>2</sup></em><em> In some cases of myopathy involving raised CPK and muscle symptoms, the patients also presented with elevated transaminases. These transaminase increases were likely to be related to the skeletal muscle effects. The majority of transaminase elevations were of Grade 1-3 toxicity and resolved upon discontinuation of treatment.</em></p><p><em><sup>3</sup></em><em> When clinical information on the patients was available to make a judgement, approximately 50% of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.</em></p><p>The safety data for the administration of Valencin via 2-minute intravenous injection are derived from two pharmacokinetic studies in healthy adult volunteers. Based on these study results, both methods of Valencin administration, the 2-minute intravenous injection and the 30-minute intravenous infusion, had a similar safety and tolerability profile. There was no relevant difference in local tolerability or in the nature and frequency of adverse reactions.</p><p>To reports any side effect(s):</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;<img src="data:image/png;base64,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" alt="" width="536" height="100" vspace="0" hspace="0" border="0" style="width:536px;height:100px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="500" height="27" vspace="0" hspace="0" border="0" style="width:500px;height:27px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, supportive care is advised. Valencin is slowly cleared from the body by haemodialysis (approximately 15% of the administered dose is removed over 4 hours) or by peritoneal dialysis (approximately 11% of the administered dose is removed over 48 hours).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Other antibacterials, ATC code: J01XX09</p><p><u>Mechanism of action</u></p><p>Valencin is a cyclic lipopeptide natural product that is active against Gram positive bacteria only.</p><p>The mechanism of action involves binding (in the presence of calcium ions) to bacterial membranes of both growing and stationary phase cells causing depolarisation and leading to a rapid inhibition of protein, DNA, and RNA synthesis. This results in bacterial cell death with negligible cell lysis.</p><p><u>PK/PD relationship</u></p><p>Valencin exhibits rapid, concentration dependent bactericidal activity against Gram positive organisms in vitro and in <em>in vivo</em> animal models. In animal models AUC/MIC and C<sub>max</sub>/MIC correlate with efficacy and predicted bacterial kill <em>in vivo</em> at single doses equivalent to human doses of 4 mg/kg and 6 mg/kg once daily.</p><p><u>Mechanisms of resistance</u></p><p>Strains with decreased susceptibility to Valencin have been reported especially during the treatment of patients with difficult-to-treat infections and/or following administration for prolonged periods. In particular, there have been reports of treatment failures in patients infected with <em>Staphylococcus aureus</em>, <em>Enterococcus faecalis</em> or <em>Enterococcus faecium</em>, including bacteraemic patients that have been associated with the selection of organisms with reduced susceptibility or frank resistance to Valencin during therapy.</p><p>The mechanism(s) of Valencin resistance is (are) not fully understood.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoint established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for Staphylococci and Streptococci (except S. pneumoniae) are Susceptible &le; 1 mg/l and Resistant &gt; 1 mg/l.</p><p><em>Susceptibility</em></p><p>The prevalence of resistance may vary geographically and over time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td><p><em>Staphylococcus aureus</em> *</p></td></tr><tr><td><p><em>Staphylococcus haemolyticus</em></p></td></tr><tr><td><p>Coagulase negative staphylococci</p></td></tr><tr><td><p><em>Streptococcus agalactiae</em>*</p></td></tr><tr><td><p><em>Streptococcus dysgalactiae</em> subsp <em>equisimilis</em>*</p></td></tr><tr><td><p><em>Streptococcus pyogenes</em>*</p></td></tr><tr><td><p>Group G streptococci</p></td></tr><tr><td><p><em>Clostridium perfringens</em></p></td></tr><tr><td><p><em>Peptostreptococcus spp </em></p></td></tr><tr><td><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td><p>Gram negative organisms</p></td></tr></tbody></table><p><em>* denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies.</em></p><p><u>Clinical efficacy in adults</u></p><p>In two adult clinical trials in complicated skin and soft tissues infections, 36% of patients treated with Daptomycin met the criteria for systemic inflammatory response syndrome (SIRS). The most common type of infection treated was wound infection (38% of patients), while 21% had major abscesses. These limitations of the patients population treated should be taken into account when deciding to use Daptomycin.</p><p>In a randomised controlled open-label study in 235 adult patients with&nbsp;<em>Staphylococcus aureus</em>&nbsp;bacteraemia (i.e, at least one positive blood culture of&nbsp;<em>Staphylococcus aureus</em>&nbsp;prior to receiving the first dose) 19 of 120 patients treated with Daptomycin met the criteria for RIE. Of these 19 patients 11 were infected with methicillin -susceptible and 8 with methicillin -resistant&nbsp;<em>Staphylococcus aureus</em>. The success rates in RIE patients are shown in the table below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td><p><strong>Population</strong></p></td><td><p><strong>Daptomycin</strong></p></td><td><p><strong>Comparator</strong></p></td><td><p><strong>Differences in Success</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>n/N (%)</strong></p></td><td><p><strong>n/N (%)</strong></p></td><td><p><strong>Rates (95% CI)</strong></p></td></tr><tr><td><p>ITT (intention to treat) Population</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>RIE</p></td><td><p>8/19 (42.1%)</p></td><td><p>7/16 (43.8%)</p></td><td><p>-1.6% (-34.6, 31.3)</p></td></tr><tr><td><p>PP (per protocol) Population</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>RIE</p></td><td><p>6/12 (50.0%)</p></td><td><p>4/8 (50.0%)</p></td><td><p>0.0% (-44.7, 44.7)</p></td></tr></tbody></table><p>Failure of treatment due to persisting or relapsing&nbsp;<em>Staphylococcus aureus</em>&nbsp;infections was observed in 19/120 (15.8%) patients treated with Daptomycin, 9/53 (16.7%) patients treated with vancomycin and 2/62 (3.2%) patients treated with an anti-staphylococcal semi-synthetic penicillin. Among these failures six patients treated with Daptomycin and one patient treated with vancomycin were infected with&nbsp;<em>Staphylococcus aureus</em>&nbsp;that developed increasing MICs of Daptomycin on or following therapy (see &ldquo;Mechanisms of resistance&rdquo; above). Most patients who failed due to persisting or relapsing&nbsp;<em>Staphylococcus aureus</em>&nbsp;infection had deep-seated infection and did not receive necessary surgical intervention.</p><p><u>Clinical efficacy in paediatric patients</u></p><p>The safety and efficacy of Daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDS-07-03) with cSSTI caused by Gram positive pathogens. Patients were enrolled in a stepwise approach into well-defined age groups and given age-dependent doses once daily for up to 14 days, as follows:</p><p>&bull; Age group 1 (n=113): 12 to 17 years treated with Daptomycin dosed at 5 mg/kg or standard-of-care (SOC);</p><p>&bull; Age group 2 (n=113): 7 to 11 years treated with Daptomycin dosed at 7 mg/kg or SOC;</p><p>&bull; Age group 3 (n=125): 2 to 6 years treated with Daptomycin dosed at 9 mg/kg or SOC;</p><p>&bull; Age group 4 (n=45): 1 to &lt; 2 years treated with Daptomycin dosed at 10 mg/kg or SOC.</p><p>The primary objective of Study DAP-PEDS-07-03 was to assess the safety of treatment. Secondary objectives included an assessment of efficacy of age-dependent doses of intravenous Daptomycin in comparison with standard-of-care therapy. The key efficacy endpoint was the sponsor-defined clinical outcome at test-of-cure (TOC), which was defined by a blinded medical director. A total of 389 subjects were treated in the study, including 256 subjects who received Daptomycin and 133 subjects who received standard-of-care. In all populations the clinical success rates were comparable between the Daptomycin and SOC treatment arms, supporting the primary efficacy analysis in the ITT population.</p><p>Summary of sponsor-defined clinical outcome at test-of-cure:</p><table border="1" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td colspan="4"><p><br />Clinical Success</p></td></tr><tr><td>&nbsp;</td><td><p>Daptomycin</p><p>n/N (%)</p></td><td><p>Comparator</p><p>n/N (%)</p></td><td><p>% difference</p></td></tr><tr><td><p>Intent-to-treat</p></td><td><p>227/257 (88.3%)</p></td><td><p>114/132 (86.4%)</p></td><td><p>2.0</p></td></tr><tr><td><p>Modified intent-to-treat</p></td><td><p>186/210 (88.6%)</p></td><td><p>92/105 (87.6%)</p></td><td><p>0.9</p></td></tr><tr><td><p>Clinically evaluable</p></td><td><p>204/207 (98.6%)</p></td><td><p>99/99 (100%)</p></td><td><p>-1.5</p></td></tr><tr><td><p>Microbiologically evaluable (ME)</p></td><td><p>164/167 (98.2%)</p></td><td><p>78/78 (100%)</p></td><td><p>-1.8</p></td></tr></tbody></table><p>The overall therapeutic response rate also was similar for the Daptomycin and SOC treatment arms for infections caused by MRSA, MSSA and&nbsp;<em>Streptococcus pyogenes&nbsp;</em>(see table below; ME population); response rates were &gt; 94% for both treatment arms across these common pathogens.</p><p>Summary of overall therapeutic response by type of baseline pathogen (ME population):</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2"><p><strong>Pathogen</strong></p></td><td colspan="2"><p><strong>Overall Success</strong><sup>a</sup>&nbsp;<strong>rate in Paediatric cSSTI</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td><p><strong>Daptomycin</strong></p></td><td><p><strong>Comparator</strong></p></td></tr><tr><td><p>Methicillin-susceptible&nbsp;<em>Staphylococcus aureus&nbsp;</em>(MSSA)</p></td><td><p>68/69 (99 %)</p></td><td><p>28/29 (97 %)</p></td></tr><tr><td><p>Methicillin-resistant&nbsp;<em>Staphylococcus aureus&nbsp;</em>(MRSA)</p></td><td><p>63/66 (96 %)</p></td><td><p>34/34 (100 %)</p></td></tr><tr><td><p><em>Streptococcus pyogenes</em></p></td><td><p>17/18 (94 %)</p></td><td><p>5/5 (100 %)</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>a</sup>&nbsp;Subjects achieving clinical success (Clinical Response of &ldquo;Cure&rdquo; or &ldquo;Improved&rdquo;) and microbiological success (pathogen&ndash;level response of &ldquo;Eradicated&rdquo; or &ldquo;Presumed Eradicated&rdquo;) are classified as overall therapeutic success.</p><p>The safety and efficacy of Daptomycin was evaluated in paediatric patients aged 1 to 17 years (Study DAP-PEDBAC-11-02) with bacteraemia caused by&nbsp;<em>Staphylococcus aureus</em>. Patients were randomised in a 2:1 ratio into the following age groups and given age-dependent doses once daily for up to 42 days, as follows:</p><p>&bull; Age group 1 (n=21): 12 to 17 years treated with Daptomycin dosed at 7 mg/kg or SOC comparator;</p><p>&bull; Age group 2 (n=28): 7 to 11 years treated with Daptomycin dosed at 9 mg/kg or SOC;</p><p>&bull; Age group 3 (n=32): 1 to 6 years treated with Daptomycin dosed at 12 mg/kg or SOC;</p><p>The primary objective of Study DAP-PEDBAC-11-02 was to assess the safety of intravenous Daptomycin versus SOC antibiotics. Secondary objectives included: Clinical outcome based on the blinded Evaluator&#39;s assessment of clinical response (success [cure, improved], failure, or non-evaluable) at the TOC Visit; and Microbiological response (success, failure, or non-evaluable) based on evaluation of Baseline infecting pathogen at TOC.</p><p>A total of 81 subjects were treated in the study, including 55 subjects who received Daptomycin and 26 subjects who received standard-of-care. No patients 1 to &lt;2 years of age were enrolled in the study. In all populations the clinical success rates were comparable in the Daptomycin versus the SOC treatment arm.</p><p>Summary of Blinded Evaluator defined clinical outcome at TOC:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="1" colspan="4" style="vertical-align:bottom"><p style="text-align:center"><strong>Clinical Success in Paediatric SAB</strong></p></td></tr><tr><td colspan="2" style="vertical-align:bottom">&nbsp;</td><td style="vertical-align:bottom"><p><strong>Daptomycin</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Comparator</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>% difference</strong></p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>Modified intent-to-treat (MITT)</p></td><td style="vertical-align:bottom"><p>46/52 (88.5 %)</p></td><td style="vertical-align:bottom"><p>19/24 (79.2 %)</p></td><td style="vertical-align:bottom"><p>9.3 %</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>Microbiologically modified intent-to-treat (mMITT)</p></td><td style="vertical-align:bottom"><p>45/51 (88.2 %)</p></td><td style="vertical-align:bottom"><p>17/22 (77.3 %)</p></td><td style="vertical-align:bottom"><p>11.0 %</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>Clinically evaluable (CE)</p></td><td style="vertical-align:bottom"><p>36/40 (90.0 %)</p></td><td style="vertical-align:bottom"><p>9/12 (75.0 %)</p></td><td style="vertical-align:bottom"><p>15.0 %</p></td></tr></tbody></table><p>The microbiological outcome at TOC for the Daptomycin and SOC treatment arms for infections caused by MRSA and MSSA are presented in the table below (mMITT population).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2"><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Microbiological Success rate in Paediatric SAB</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Daptomycin</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-susceptible&nbsp;<em>Staphylococcus aureus&nbsp;</em>(MSSA)</p></td><td><p>43/44 (97.7 %)</p></td><td><p>19/19 (100.0 %)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant&nbsp;<em>Staphylococcus aureus&nbsp;</em>(MRSA)</p></td><td><p>6/7 (85.7 %)</p></td><td><p>3/3 (100.0 %)</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daptomycin pharmacokinetics are generally linear and time-independent at doses of 4 to 12 mg/kg administered as a single daily dose by 30-minute intravenous infusion for up to 14 days in healthy volunteers. Steady-state concentrations are achieved by the third daily dose.</p><p>Daptomycin administered as a 2-minute intravenous injection also exhibited dose proportional pharmacokinetics in the approved therapeutic dose range of 4 to 6 mg/kg. Comparable exposure (AUC and C<sub>max</sub>) was demonstrated in healthy adult subjects following administration of Daptomycin as a 30-minute intravenous infusion or as a 2-minute intravenous injection.</p><p>Animal studies showed that Daptomycin is not absorbed to any significant extent after oral administration.</p><p><u>Distribution</u></p><p>The volume of distribution at steady state of Daptomycin in healthy adult subjects was approximately 0.1 l/kg and was independent of dose. Tissue distribution studies in rats showed that Daptomycin appears to only minimally penetrate the blood-brain barrier and the placental barrier following single and multiple doses.</p><p>Daptomycin is reversibly bound to human plasma proteins in a concentration independent manner. In healthy adult volunteers and adult patients treated with Daptomycin, protein binding averaged about 90% including subjects with renal impairment.</p><p><u>Biotransformation</u></p><p>In <em>in vitro</em> studies, Daptomycin was not metabolised by human liver microsomes. <em>In vitro</em> studies with human hepatocytes indicate that Daptomycin does not inhibit or induce the activities of the following human cytochrome P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4. It is unlikely that Daptomycin will inhibit or induce the metabolism of medicinal products metabolised by the P450 system.</p><p>After infusion of <sup>14</sup>C-Daptomycin in healthy adults, the plasma radioactivity was similar to the concentration determined by microbiological assay. Inactive metabolites were detected in urine, as determined by the difference in total radioactive concentrations and microbiologically active concentrations. In a separate study, no metabolites were observed in plasma, and minor amounts of three oxidative metabolites and one unidentified compound were detected in urine. The site of metabolism has not been identified.</p><p><u>Elimination</u></p><p>Daptomycin is excreted primarily by the kidneys. Concomitant administration of probenecid and Daptomycin has no effect on Daptomycin pharmacokinetics in humans suggesting minimal to no active tubular secretion of Daptomycin.</p><p>Following intravenous administration, plasma clearance of Daptomycin is approximately 7 to 9 ml/h/kg and its renal clearance is 4 to 7 ml/h/kg.</p><p>In a mass balance study using radiolabelled material, 78% of the administered dose was recovered from the urine based on total radioactivity, whilst urinary recovery of unchanged Daptomycin was approximately 50% of the dose. About 5% of the administered radiolabel was excreted in the faeces.</p><p><strong>Special populations</strong></p><p><em><u>Elderly</u></em></p><p>Following administration of a single 4 mg/kg intravenous dose of Daptomycin over a 30-minute period, the mean total clearance of Daptomycin was approximately 35% lower and the mean AUC<sub>0-&infin;</sub> was approximately 58% higher in elderly subjects (&ge; 75 years of age) compared with those in healthy young subjects (18 to 30 years of age). There were no differences in C<sub>max</sub>. The differences noted are most likely due to the normal reduction in renal function observed in the geriatric population.</p><p>No dose adjustment is necessary based on age alone. However, renal function should be assessed and the dose should be reduced if there is evidence of severe renal impairment.</p><p><em>Children and adolescents (1 to 17 years of age)</em></p><p>The pharmacokinetics of Daptomycin in paediatric subjects was evaluated in 3 single-dose pharmacokinetic studies. After a single 4 mg/kg dose of Daptomycin, total clearance normalized by weight and elimination half-life of Daptomycin in adolescents (12-17 years of age) with Gram-positive infection were similar to adults. After a single 4 mg/kg dose of Daptomycin, total clearance of Daptomycin in children 7-11 years of age with Gram-positive infection was higher than in adolescents, whereas elimination half-life was shorter. After a single 4, 8, or 10 mg/kg dose of Daptomycin, total clearance and elimination half-life of Daptomycin in children 2-6 years of age were similar at different doses; total clearance was higher and elimination half-life was shorter than in adolescents. After a single 6 mg/kg dose of Daptomycin, the clearance and elimination half-life of Daptomycin in children 13-24 months of age were similar to children 2-6 years of age who received a single 4-10 mg/kg dose. The results of these studies show that exposures (AUC) in paediatric patients across all doses are generally lower than those in adults at comparable doses.</p><p><em>Paediatric patients with cSSTI</em></p><p>A Phase 4 study (DAP-PEDS-07-03) was conducted to assess safety, efficacy, and pharmacokinetics of Daptomycin in paediatric patients (1 to 17 years old, inclusive) with cSSTI caused by Gram-positive pathogens. Daptomycin pharmacokinetics in patients in this study are summarized in Table 2. Following administration of multiple doses, Daptomycin exposure was similar across different age groups after dose adjustment based on body weight and age. Plasma exposures achieved with these doses were consistent with those achieved in the adult cSSTI study (following 4 mg/kg once daily in adults).</p><p>Table 2 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric cSSTI Patients (1 to 17 Years of Age) in Study DAP-PEDS-07-03</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Age Range</p></td><td><p>12-17 years (N=6)</p></td><td><p>7-11 years (N=2)<sup>a</sup></p></td><td><p>2-6 years (N=7)</p></td><td><p>1 to &lt;2 years (N=30)<sup>b</sup></p></td></tr><tr><td><p>Dose</p><p>Infusion Time</p></td><td><p>5 mg/kg</p><p>30 minutes</p></td><td><p>7 mg/kg</p><p>30 minutes</p></td><td><p>9 mg/kg</p><p>60 minutes</p></td><td><p>10 mg/kg</p><p>60 minutes</p></td></tr><tr><td><p>AUC0-24hr (&mu;g&times;hr/ml)</p></td><td><p>387 (81)</p></td><td><p>438</p></td><td><p>439 (102)</p></td><td><p>466</p></td></tr><tr><td><p>C<sub>max</sub>&nbsp;(&mu;g/ml)</p></td><td><p>62.4 (10.4)</p></td><td><p>64.9, 74.4</p></td><td><p>81.9 (21.6)</p></td><td><p>79.2</p></td></tr><tr><td><p>Apparent t1/2 (hr)</p></td><td><p>5.3 (1.6)</p></td><td><p>4.6</p></td><td><p>3.8 (0.3)</p></td><td><p>5.04</p></td></tr><tr><td><p>CL/wt (ml/hr/kg)</p></td><td><p>13.3 (2.9)</p></td><td><p>16.0</p></td><td><p>21.4 (5.0)</p></td><td><p>21.5</p></td></tr></tbody></table><p><em>Pharmacokinetic parameter values estimated by noncompartmental analysis</em></p><p><em><sup>a</sup></em><em>Individual values reported as only two patients in this age group provided pharmacokinetic samples to enable pharmacokinetic analysis; AUC, apparent t1/2 and CL/wt could be determined for only one of the two patients</em></p><p><em><sup>b</sup></em><em>Pharmacokinetic analysis conducted on the pooled pharmacokinetic profile with mean concentrations across subjects at each time point</em></p><p><em>Paediatric patients with SAB</em></p><p>A Phase 4 study (DAP-PEDBAC-11-02) was conducted to assess safety, efficacy, and pharmacokinetics of Daptomycin in paediatric patients (1 to 17 years old, inclusive) with SAB. Daptomycin pharmacokinetics inpatients in this study are summarized in Table 3. Following administration of multiple doses, Daptomycin exposure was similar across different age groups after dose adjustment based on body weight and age. Plasma exposures achieved with these doses were consistent with those achieved in the adult SAB study (following 6 mg/kg once daily in adults).</p><p>Table 3 Mean (Standard Deviation) of Daptomycin Pharmacokinetics in Paediatric SAB Patients (1 to 17 Years of Age) in Study DAP-PEDBAC-11-02</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Age Range</p></td><td><p>12-17 years (N=13)</p></td><td><p>7-11 years (N=19)</p></td><td><p>1 to 6 years (N=19)*</p></td></tr><tr><td><p>Dose</p><p>Infusion Time</p></td><td><p>7 mg/kg</p><p>30 minutes</p></td><td><p>9 mg/kg</p><p>30 minutes</p></td><td><p>12 mg/kg</p><p>60 minutes</p></td></tr><tr><td><p>AUC0-24hr (&mu;g&times;hr/ml)</p></td><td><p>656 (334)</p></td><td><p>579 (116)</p></td><td><p>620 (109)</p></td></tr><tr><td><p>C<sub>max</sub>&nbsp;(&mu;g/ml)</p></td><td><p>104 (35.5)</p></td><td><p>104 (14.5)</p></td><td><p>106 (12.8)</p></td></tr><tr><td><p>Apparent t1/2 (hr)</p></td><td><p>7.5 (2.3)</p></td><td><p>6.0 (0.8)</p></td><td><p>5.1 (0.6)</p></td></tr><tr><td><p>CL/wt (ml/hr/kg)</p></td><td><p>12.4 (3.9)</p></td><td><p>15.9 (2.8)</p></td><td><p>19.9 (3.4)</p></td></tr></tbody></table><p><em>Pharmacokinetic parameter values estimated using a model-based approach with sparsely collected pharmacokinetic samples from individual patients in the study.</em></p><p><em>*Mean (Standard Deviation) calculated for patients 2 to 6 years of age, since no patients 1 to &lt;2 years of age were enrolled in the study. Simulation using a population pharmacokinetic model demonstrated that the AUCss (area under the concentration-time curve at steady state) of Daptomycin in paediatric patients 1 to &lt;2 years of age receiving 12 mg/kg once daily would be comparable to that in adult patients receiving 6 mg/kg once daily.</em></p><p>&nbsp;<em>Obesity</em></p><p>Relative to non-obese subjects Daptomycin systemic exposure measured by AUC was about 28% higher in moderately obese subjects (Body Mass Index of 25-40 kg/m<sup>2</sup>) and 42% higher in extremely obese subjects (Body Mass Index of &gt; 40 kg/m<sup>2</sup>). However, no dose adjustment is considered to be necessary based on obesity alone.</p><p><em>Gender</em></p><p>No clinically significant gender-related differences in Daptomycin pharmacokinetics have been observed.</p><p><em>Race</em></p><p>No clinically significant differences in daptomycin pharmacokinetics have been observed in Black or Japanese subjects relative to Caucasian subjects.</p><p><em>Renal impairment</em></p><p>Following administration of a single 4 mg/kg or 6 mg/kg intravenous dose of Daptomycin over a 30-minute period to adult subjects with various degrees of renal impairment, total Daptomycin clearance (CL) decreased and systemic exposure (AUC) increased as renal function (creatinine clearance) decreased.</p><p>Based on pharmacokinetic data and modelling, the Daptomycin AUC during the first day after administration of a 6 mg/kg dose to patients on HD or CAPD was 2-fold higher than that observed in adult patients with normal renal function who received the same dose. On the second day after administration of a 6 mg/kg dose to HD and CAPD adult patients the daptomcyin AUC was approximately 1.3-fold higher than that observed after a second 6 mg/kg dose in adult patients with normal renal function. On this basis, it is recommended that patients on HD or CAPD receive Daptomycin once every 48 hours at the dose recommended for the type of infection being treated (see section 4.2).</p><p>The dosage regimen for Daptomycin in paediatric patients with renal impairment has not been established.</p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of Daptomycin is not altered in subjects with moderate hepatic impairment (Child-Pugh B classification of hepatic impairment) compared with healthy volunteers matched for gender, age and weight following a single 4 mg/kg dose. No dosage adjustment is necessary when administering Daptomycin in patients with moderate hepatic impairment. The pharmacokinetics of Daptomycin in patients with severe hepatic impairment (Child-Pugh C classification) have not been evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Valencin administration was associated with minimal to mild degenerative/regenerative changes in skeletal muscle in the rat and dog. Microscopic changes in skeletal muscle were minimal (approximately 0.05 % of myofibres affected) and at the higher doses were accompanied by elevations in CPK. No fibrosis or rhabdomyolysis was observed. Depending on the study duration, all muscle effects, including microscopic changes, were fully reversible within 1-3 months following cessation of dosing. No functional or pathological changes in smooth or cardiac muscle were observed.</p><p>The lowest observable effect level (LOEL) for myopathy in rats and dogs occurred at exposure levels of 0.8 to 2.3-fold the human therapeutic levels at 6 mg/kg (30-minute intravenous infusion) for patients with normal renal function. As the pharmacokinetics (see section 5.2) is comparable, the safety margins for both methods of administration are very similar.</p><p>A study in dogs demonstrated that skeletal myopathy was reduced upon once daily administration as compared to fractionated dosing at same total daily dose, suggesting that myopathic effects in animals were primarily related to time between doses.</p><p>Effects on peripheral nerves were observed at higher doses than those associated with skeletal muscle effects in adult rats and dogs, and were primarily related to plasma Cmax. Peripheral nerve changes were characterised by minimal to slight axonal degeneration and were frequently accompanied by functional changes. Reversal of both the microscopic and functional effects was complete within 6 months post-dose. Safety margins for peripheral nerve effects in rats and dogs are 8- and 6-fold, respectively, based on comparison of Cmax&nbsp;values at the No Observed Effect Level (NOEL) with the Cmax&nbsp;achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function.</p><p>The findings of&nbsp;in vitro&nbsp;and some&nbsp;in vivo&nbsp;studies designed to investigate the mechanism of Valencin myotoxicity indicate that the plasma membrane of differentiated spontaneously contracting muscle cells is the target of toxicity. The specific cell surface component directly targeted has not been identified. Mitochondrial loss/damage was also observed; however the role and significance of this finding in the overall pathology are unknown. This finding was not associated with an effect on muscle contraction.</p><p>In contrast to adult dogs, juvenile dogs appeared to be more sensitive to peripheral nerve lesions as compared to skeletal myopathy. Juvenile dogs developed peripheral and spinal nerve lesions at doses lower than those associated with skeletal muscle toxicity.</p><p>In neonatal dogs, Valencin caused marked clinical signs of twitching, muscle rigidity in the limbs, and impaired use of limbs, which resulted in decreases in body weight and overall body condition at doses &ge; 50 mg/kg/day and necessitated early discontinuation of treatment in these dose groups. At lower dose levels (25 mg/kg/day), mild and reversible clinical signs of twitching and one incidence of muscle rigidity were observed without any effects on body weight. There was no histopathological correlation in the peripheral and central nervous system tissue, or in the skeletal muscle, at any dose level, and the mechanism and clinical relevance for the adverse clinical signs are therefore unknown.</p><p>Reproductive toxicity testing showed no evidence of effects on fertility, embryofoetal, or postnatal development. However, Valencin can cross the placenta in pregnant rats (see section 5.2). Excretion of Valencin into milk of lactating animals has not been studied.</p><p>Long-term carcinogenicity studies in rodents were not conducted. Valencin was not mutagenic or clastogenic in a battery of&nbsp;in vivo&nbsp;and&nbsp;in vitro&nbsp;genotoxicity tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Chemical and physical in-use stability on the reconstituted solution in the vial has been demonstrated for 12 hours at 25 &deg;C and up to 48 hours if stored under refrigeration (2&deg;C &ndash; 8&deg;C). However, from a microbiological point of view the product should be used immediately. If not used immediately, in-use storage times are the responsibility of the user and would normally not be longer than 24 hours at 2 &deg;C &ndash; 8 &deg;C unless reconstitution /dilution has taken place in controlled and validate aseptic conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>500 mg: 15 ml type I clear glass vials closed with a rubber stopper and an aluminium closure with a plastic flip off seal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adults, Valencin may be administered intravenously as an infusion over 30 minutes or as an injection over 2 minutes. Valencin should not be administered as a 2-minute injection to paediatric patients. Paediatric patients 7 to 17 years old should receive Valencin infused over 30 minutes. In paediatric patients under 7 years old receiving a 9-12 mg/kg dose, Valencin should be administered over 60 minutes (see sections 4.2 and 5.2). Preparation of the solution for infusion requires an additional dilution step as detailed below.</p><p>Valencin <u>given as 30 or 60-minute intravenous infusion</u></p><p>A 50 mg/ml concentration of Valencin 500 mg powder for infusion is obtained by reconstituting the lyophilised product with 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection.</p><p>The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.</p><p><em>Valencin</em> <em>500 mg powder for solution for injection or infusion</em></p><p>To prepare Valencin for intravenous infusion, please adhere to the following instructions:</p><p>Aseptic technique should be used throughout to reconstitute or dilute lyophilised Valencin.</p><p><u>For Reconstitution:</u></p><p>1. The polypropylene flip off cap should be removed to expose the central portions of the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p>2. The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p>3. Finally the vial should be gently rotated/swirled for a few minutes as needed to obtain a clear reconstituted solution. Vigorous shaking/agitation should be avoided to prevent foaming of the product.</p><p>4. The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Valencin range in colour from pale yellow to light brown.</p><p>5. The reconstituted solution should then be diluted with sodium chloride 9 mg/ml (0.9 %) (typical volume 50 ml).</p><p><u>For Dilution:</u></p><p>1. Slowly remove the appropriate reconstituted liquid (50 mg Valencin/ml) from the vial using a new sterile needle that is 21 gauge or smaller in diameter by inverting the vial in order to allow the solution to drain towards the stopper. Using a syringe, insert the needle into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove the required solution from the inverted vial.</p><p>2. Expel air, large bubbles, and any excess solution in order to obtain the required dose.</p><p>3. Transfer the required reconstituted dose into 50 ml sodium chloride 9 mg/ml (0.9 %).</p><p>4. The reconstituted and diluted solution should then be infused intravenously over 30 or 60 minutes as directed in section 4.2.</p><p>The following have been shown to be compatible when added to Cubicin containing infusion solutions: aztreonam, ceftazidime, ceftriaxone, gentamicin, fluconazole, levofloxacin, dopamine, heparin and lidocaine.</p><p><u>Valencin given as 2-minute intravenous injection (adult patients only)</u></p><p>Water should not be used for reconstitution of Valencin for intravenous injection. Valencin should only be reconstituted with sodium chloride 9 mg/ml (0.9 %).</p><p>A 50 mg/ml concentration of Valencin 500 mg powder for injection is obtained by reconstituting the lyophilised product with 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection.</p><p>The lyophilised product takes approximately 15 minutes to dissolve. The fully reconstituted product will appear clear and may have a few small bubbles or foam around the edge of the vial.</p><p><em>Valencin 500 mg powder for solution for injection or infusion</em></p><p>To prepare Valencin for intravenous injection, please adhere to the following instructions:</p><p>Aseptic technique should be used throughout to reconstitute lyophilised Cubicin.</p><p>1. The polypropylene flip off cap should be removed to expose the central portions of the rubber stopper. Wipe the top of the rubber stopper with an alcohol swab or other antiseptic solution and allow to dry. After cleaning, do not touch the rubber stopper or allow it to touch any other surface. Draw 10 ml of sodium chloride 9 mg/ml (0.9 %) solution for injection into a syringe using a sterile transfer needle that is 21 gauge or smaller in diameter, or a needleless device, then slowly inject through the centre of the rubber stopper into the vial pointing the needle towards the wall of the vial.</p><p>2. The vial should be gently rotated to ensure complete wetting of the product and then allowed to stand for 10 minutes.</p><p>3. Finally the vial should be gently rotated/swirled for a few minutes as needed to obtain a clear reconstituted solution. Vigorous shaking/agitation should be avoided to prevent foaming of the product.</p><p>4. The reconstituted solution should be checked carefully to ensure that the product is in solution and visually inspected for the absence of particulates prior to use. Reconstituted solutions of Valencin range in colour from pale yellow to light brown.</p><p>5. Slowly remove the reconstituted liquid (50 mg Valencin/ml) from the vial using a sterile needle that is 21 gauge or smaller in diameter.</p><p>6. Invert the vial in order to allow the solution to drain towards the stopper. Using a new syringe, insert the needle into the inverted vial. Keeping the vial inverted, position the needle tip at the very bottom of the solution in the vial when drawing the solution into the syringe. Before removing the needle from the vial, pull the plunger all the way back to the end of the syringe barrel in order to remove all of the solution from the inverted vial.</p><p>7. Replace needle with a new needle for the intravenous injection.</p><p>8. Expel air, large bubbles, and any excess solution in order to obtain the required dose.</p><p>9. The reconstituted solution should then be injected intravenously slowly over 2 minutes as directed in section 4.2.</p><p>Valencin vials are for single-use only.</p><p>From a microbiological point of view, the product should be used immediately after reconstitution (see section 6.3).</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma Company (SPC)
King Fahad Road –Riyadh Gallery Mall, Gate A1, 
3rd floor Sudair pharma office, Building 7639, 
Riyadh 12262, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January-2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>